6 protocol(s) meet the specified criteria
Drug: ARA-C
Protocol No.TitleStatus
CALGB10403An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)Open (affiliates only)
CALGB10503Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 YearsOpen (affiliates only)
CALGB10603A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)Open (affiliates only)
CALGB50403A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell LymphomaOpen (affiliates only)
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open